Precision Medicine Initiative (PMI) Committee Meeting

July 26, 2023

NIH NATIONAL CANCER INSTITUTE

Agenda

- Role Call
- Project Status Updates
- Cohort Migration Workflow Presentation
- Project Discussion Items
- Review FAQs
- Next Steps

Stakeholder Representation

- ✓ Alliance
- ✓ ECOG-ACRIN
- ✓ CCTG
- ✓ NRG
- ✓ COG
- ✓ SWOG
- ✓ Nationwide
- ✓ MD Anderson
- ✓ MOCHA

Project Status Updates

Project Updates

PMI Project Deliverable	Target Release Date	Release Vehicle
ComboMATCH changes (Disease fields, histology, behavior field code)	Released: July 17, 2023	Screening Protocol EC Template v2.0
Designated Labs for Combo	July 31, 2023	Screening Protocol EC Template v3.0
Re-Screening ComboMATCH	August 18, 2023	Screening Protocol Re-Screening EC Template v1.0
MyeloMATCH Tx Protocol Crossover (for S01, CTG01 and EA02)	October 3, 2023	Part of the existing Treatment Protocol workflow.
Cohort Migration	September 25, 2023	Treatment Protocol Cohort Migration EC Template v1.0
Re-Screening MM	Oct 10, 2023	Screening Protocol Re-Screening EC Template v2.0
STMF	Oct 16, 2023	PMI Screening Protocol ALS v2.0
CLIA	Oct 16, 2023	PMI Screening Protocol ALS v2.0
Path	Oct 16, 2023	PMI Screening Protocol ALS v2.0
PMI Screening Protocol ALS v2.0	~ mid-October 2023	Target to start Group Beta UAT
MyeloMATCH Stratification	Oct 20, 2023	Part of existing Treatment Protocol Workflow

EC Screening Template Release Schedule

SWOG Question: Does SWOG need to continue study build activities on ALSv1.0 or wait until ALSv2.0.

NCI Leadership is reviewing the options and will provide an update via email by next week.

Release	Details	Tentative Release Date
V1.0	Production Release	February 15th 2023
V2.0	Includes CM changes (Disease fields, histology, behavior field code)	July 17th 2023
V3.0	Includes updates for Designated Labs (DLAP fields)	August 18th 2023
V4.0	MM MSRP changes (Provisional Diagnosis Question)	TBD

PMI Form Mappings

Group	Status Update
Alliance	Pending, finalization & meetings scheduled with NCI Leadership for week of 08/1/2023.
COG	Pending finalization.

Group Roadblocks

Group	7/12/2023	7/26/2023
ECOG-ACRIN	• *Need the EC template*	
SWOG	• *Need v4 to complete study build for MM*	• *Need v4 to complete study build for MM* • *Need confirmation and timeline on ineligible process*
NRG	• *Need more information on the OPEN process; will walk through the Cohort Migration workflow*	• *No questions*
Alliance	• *Waiting for Cohort Migration Template – Is there anything the project team to provide to help prepare. Knowing what the variables are…will add that to next presentation*	• *No questions*
CCTG	• EC v2 template; keeping MSRP on hold • Need patients for UAT testing	• *No questions*
COG	• No roadblocks	• *No updates;* • *Waiting on mappings*

Cohort Migration Workflow Presentation

Cohort Migration & pending Fact Sheet details

DRAFT PMI CDISC Treatment Protocol Cohort Migration EC Template Fact Sheet

III. CDE Requirements for PMI Treatment Protocol Cohort Migration EC Forms/Worksheets (caDSR II Form PID *tbd*):

PMI Treatment Protocol Cohort Migration CDE Requirements					
PMI EC CDE PID	**PMI EC QT/Prompt**	**Combo MATCH**	**Myelo MATCH**	**OPEN Widget Type**	**Notes**
Treatment Protocol Module 1					
6380045	**Screening protocol ID**	Conditional*	*Optional*	Edit Box	Groups should designate this module to the "Pre-Requisite" screen under the OPEN Questions screen. These fields will be (1) validated against the data on the CTSU Demography Standard Form, (2) are required for successful transactions for the PMI CDISC Off Treatment (OT) and PMI CDISC Consent Withdrawal (CW) Forms, and (3) used to validate patient enrollment in OPEN to the correct treatment protocol per treatment assignment from MATCHBox.
6380049	**Screening participant ID**	Conditional*	*Optional*	Edit Box	
Treatment Protocol Module 2					
10987207	**Cohort migration assignment**	Conditional*	*Optional*	*tbd*	This field will specify the Cohort Migration details for a patient. *Instructional Text for OPEN Screen: "Patients receiving the control drug who experience disease progression may elect to migrate to another cohort and receive combination treatment. Click 'Request' to see if the patient is eligible; click 'Cancel' to withdraw a request."*

**Use of this form conditional/protocol-specific for ComboMATCH; if said ComboMATCH protocol includes cohort migration, then this form and the corresponding fields are required required.*

PMI Project Discussion Items

OPEN Notification

- During testing, ECOG-ACRIN raised (on a PMI called back in February) that they did not have visibility into whether they successfully registered a participant in OPEN ***or*** if registration failed.
- The ComboMATCHBox team has just completed a ticket for notifying ECOG-ACRIN of successful/unsuccessful registration. Who at ECOG-ACRIN would need to receive the notifications/what email addresses need to be added to the distribution list?

Open Discussion

Next Steps

Next Steps

Next meeting will be on 8/9/2023 at 1:00pm EST

Agenda

- Role Call
- Project Status Update
- Group Status Update
- Review FAQs

Communication

Contact the PMI Mailbox for any PMI related questions & comments

pmistandards@nih.gov

The project team will respond within 48 hours with a response or a follow up

PMI Wiki

https://wiki.nci.nih.gov/display/CDISC/Precision+Medicine+Initiative

All presentations, recordings, minutes, project documents and releases will be posted on this wiki

NATIONAL CANCER INSTITUTE

www.cancer.gov

www.cancer.gov/espanol

Appendix

Target Timeline

Nov – Mid Dec 2022

Group Activities
- Develop Study-specific Rave CRFs

NCI Activities
- ComboMATCH UAT Matchbox Environment
- MyeloMATCH UAT Matchbox Environment
- MATCHBox & OPEN Integrations for UAT
- Prepare Beta Screening & Treatment ALS files

Mid Dec 2022

NCI Activities
- Release EC Templatev1
- Release Beta Screening Protocol ALS
- Release Beta Treatment Protocol ALS
- aMOI List Approval and MATCHBox Upload

Mid Dec to Jan 30, 2023

Group Activities
- UAT Testing

NCI Activities
- Iterative updates to test findings (show-stoppers)

Target Timeline

Jan 31, 2023

NCI Activities
- Release EC Template v1
- Release Prod Screening Protocol ALS
- Release Prod Treatment Protocol ALS
- Release Prod Central Study ALS
- Release NCI OPEN Integrations for Prod
- Release NCI Genexus Installation (MyeloMATCH)

Jan 31 to Feb 14, 2023

NCI + Group Activities
- Support Group Study Builds

Feb 14, 2023

NCI + Group Activities
- Launch BOTH Initiatives

Spring 2023

NCI Activities
- Release Additional ALS(s)

ComboMATCH Priority 1 List

Study #	Document Number	Document Title	Group	Current Status	Next Steps	Primary Agent Name (P) Other Agent Name (O)
1	EAY191	Molecular Analysis for Combination Therapy Choice (ComboMATCH)	ECOG-ACRIN	8/15/2022 Approval on Hold	Revision 3 back from CIRB with approval. On hold for DTL, funding sheet and IND filing.	
2	EAY191-N4	Molecular Analysis for Combination Therapy Choice (ComboMATCH) EAY191-N4: A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers A ComboMATCH Treatment Trial	NRG	8/15/2022 Approval on Hold	Revision 4 back from CIRB with approval. On hold for DTL, funding sheet and IND filing.	(P) Olaparib (AZD2281) (747856) (O) Selumetinib (AZD6244 hydrogen sulfate) (748727)
3	EAY191-E4	A ComboMATCH Treatment Trial ComboMATCH Treatment Trial E4: Nilotinib and Paclitaxel in Patients with Prior Taxane-Treated Solid Tumors	ECOG-ACRIN	8/26/2022 Approval on Hold	Revision 3 back from CIRB with approval. On hold for DTL, funding sheet and IND filing.	(P) Nilotinib (747599) (O) Paclitaxel (Taxol) (673089)
4	EAY191-N2	A ComboMATCH Treatment Trial EAY191-N2: Phase 2 Trial of Fulvestrant and Binimetinib in Patients with Hormone Receptor-Positive Metastatic Breast Cancer with a Frameshift or Nonsense Mutation or Genomic Deletion in NF1	NRG	8/26/2022 Approval on Hold	Revision 3 back from CIRB with approval. On hold for DTL, funding sheet and IND filing.	(P) Binimetinib (788187) (O) Fulvestrant (Faslodex) (719276)
5	EAY191-S3	Phase 2 Study of Paclitaxel + Ipatasertib in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors	SWOG	8/29/2022 Approval on Hold	Revision 4 back from CIRB with approval. On hold for DTL, funding sheet and IND filing.	(P) Ipatasertib (781451) (O) Paclitaxel (Taxol) (673089)

ComboMATCH Priority 2 List

Study #	Document Number	Document Title	Group	Current Status	Next Steps	Primary Agent Name (P) Other Agent Name (O)
6	EAY191-A6	A ComboMATCH Treatment Trial: FOLFOX in Combination with Binimetinib as 2nd Line Therapy for Patients with Advanced Biliary Tract Cancers with MAPK Pathway Alterations	Alliance	Approval on Hold 9/14/2022	Rev 4 approved by CIRB on 10/24. CTEP currently reviewing stips.	(P) Binimetinib (788187) (O) OXALIplatin (Eloxatin) (266046) (O) 5-Fluorouracil (5-FU) (19893) (O)Leucovorin calcium (3590)
7	EAY191-A3	Palbociclib and Binimetinib in RAS-Mutant Cancers	Alliance	Approval on Hold 8/26/2022	Rev 2 sent to CIRB . Reviewed on 10/6, study team responding to stips	(P) Palbociclib (PD-0332991) (772256) (O) Binimetinib (788187)

ComboMATCH Priority 3 List

Study #	Document Number	Document Title	Group	Current Status	Next Steps	Primary Agent Name (P) Other Agent Name (O)
8	EAY191-A2	Olaparib Plus Low-Dose Alpelisib for Breast Cancer	Alliance	In Review 4/4/2022	Rev 3 recv;d 10/19, currently with LR. Looks like it'll be another disapproval. Not yet sent to CIRB for initial review.	(P) Olaparib (AZD2281) (747856) (O) Alpelisib (BYL719) (801658)
9	EAY191-C1	Phase 2 Subprotocol of the Combination of a MEK Inhibitor and a Pan-RAF Inhibitor in Patients with Relapsed/Refractory Tumors Harboring Activating MAPK Pathway Mutations	COG	In Review 9/29/2022	Protocol reviewed at PRC 10/20; CR is being put together	(P) Selumetinib (AZD6244 hydrogen sulfate) (748727) (O) DAY101 (TAK-580, MLN-2480) (800798)
10	EAY191-E5	ComboMATCH Treatment Trial E5: A Randomized Phase II Study of AMG 510 (Sotorasib) with or Without Panitumumab in Advanced Solid Tumors	ECOG-ACRIN	In Review 2/22/2022	Waiting for revision 2 since 9/28; reminder was sent to EA 10/24	(P) AMG 510 (Sotorasib) (825510) (O) Panitumumab (742319)
11	EAY191-N5	Molecular Analysis for Combination Therapy Choice (ComboMATCH) EAY191-N5: A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination with Palbociclib, a CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors A ComboMATCH Treatment Trial	NRG	In Review 11/22/2021	Rev 3 disapproval sent 10/15; waiting for Rev 4	(P) Neratinib (783782) (O) Palbociclib (PD-0332991) (772256)

MyeloMATCH Priority 1 List

Study #	Document Number	Document Title	Group	Current Status	Next Steps
1	MYELOMATCH	Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials	SWOG	11/12/2021: Approval on Hold	CIRB Reviewed on 9/15, version with stips under CTEP review now.
2	MM1YA-S01	A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7 + 3) to (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, and Azacitidine + Venetoclax in Patients Aged 59 or Younger with High-Risk (Adverse) Acute Myeloid Leukemia; A MYELOMATCH Clinical Trial	SWOG	9/2/2022: Approval on Hold	CIRB Reviewed on 9/15, version with stips under CTEP review now.
3	MM1YA-CTG01	A Measurable Residual Disease (MRD) Driven, Phase II Study of Venetoclax Plus Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk Acute Myeloid Leukemia: A Tier 1 MYELOMATCH Clinical Trial	CCTG	9/2/2022: Approval on Hold	CIRB Review Oct 6, responding to stips
6	MM1OA-EA02 (Concept)	A Randomized Phase II Study of HMA-Based Therapies for the Treatment of Older Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia: A myeloMATCH Treatment Trial	ECOG-ACRIN	8/29/2022: Approved, no protocol yet	Waiting for protocol

MyeloMATCH Priority 2 List

Study #	Document Number	Document Title	Group	Current Status	Next Steps
4	MM2YA-EA01	Eradicating Measurable Residual Disease in Patients with Acute Myeloid Leukemia (AML) Prior to StEm Cell Transplantation (ERASE): A MyeloMATCH Treatment Trial	ECOG-ACRIN	1/21/2022: In Review	Reviewed by CIRB, responding to stips
5	MM1OA-S02	A Randomized Phase II Study of Targeted Agents with the Oral DNMT1 Inhibitor Cedazuridine-Decitabine (ASTX727) for the Treatment of Newly Diagnosed TP53-Mutated Acute Myeloid Leukemia in Older Patients: A myeloMATCH Treatment Trial	SWOG	10/17/2022: In Review	Scheduled for PRC 11/4
7	MM1MDS-EA03 (Concept	ERADICATE MDS with TP53 Study: Efficacy of taRgeted Agents Combinations with Oral DNMT1 Inhibitor C-DEC (ASTX727) for TrEatment of Higher Risk myElodysplastic Syndromes with TP53 Mutations: A Non-Comparative, Parallel, Multi-Arm Phase 2 Study	ECOG-ACRIN	8/12/2022: Approval on hold, waiting for drug commitment	W+A6:G8aiting for Astex commitment, Genentech has provided commitment on 10/20

Review Schemas

EAY191-N4


Protocol N4
EAY191-N4
People with:
• RAS Pathway Mutant (KRAS, NRAS, HRAS, NF1, BRAF)
• AND Ovarian (including primary peritoneal and fallopian tube) OR Endometrial Cancer
• Excludes:
◦ Prior MEK inhibitors
◦ Prior PARP inhibitors with disease progression (Prior PARP inhibitors are allowed if there was no disease progression)
Cohort 1
EAY191-N4.C1
People with Ovarian (including primary peritoneal and fallopian tube) Cancer
N = 85
Cohort 2
EAY191-N4.C2
People with Endometrial Cancer
N = 80
R
R
Treatment Regimen 1
EAY191-N4.C1.R1
(Selumetinib + Olaparib)
Treatment Regimen 2
EAY191-N4.C1.R2
(Selumetinib)
Participants on Treatment Regimen 2 that progress are eligible to crossover to Treatment Regimen 1 in the same Cohort
Treatment Regimen 1
EAY191-N4.C2.R1
(Selumetinib + Olaparib)
Treatment Regimen 2
EAY191-N4.C2.R2
(Selumetinib)
KEY
R
Randomization

EAY191-E4


Protocol E4
EAY191-E4
People with:
• Previous taxane therapy (metastatic setting)
• Excludes:
◦ Platinum-resistant epithelial serous ovarian cancer
◦ cKIT variants
◦ PDGFRA D842V variants
N = 40
Treatment Regimen 1
EAY191-E4.R1
(Nilotinib + Paclitaxel)

EAY191-N2- Draft



EAY191-S3


Protocol S3
EAY191-S3
People with:
• Advanced or metastatic non-breast solid tumors
• A mutation in AKT1/AKT2/AKT3
• Progressed on prior taxane therapy
Excludes:
• Mutations in KRAS, NRAS, HRAS or BRAF
• Prior AKT inhibitor
N = 33
Treatment Regimen 1
EAY191-S3.R1
(Paclitaxel + Ipatasertib)

MMIYA-CTG01 Draft